Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Purchases 20,000 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc bought 20,000 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was acquired at an average cost of $8.24 per share, for a total transaction of $164,800.00. Following the purchase, the director owned 5,234,578 shares in the company, valued at approximately $43,132,922.72. This trade represents a 0.38% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, November 10th, Orbimed Advisors Llc bought 22,700 shares of Electra Therapeutics stock. The shares were acquired at an average price of $8.45 per share, for a total transaction of $191,815.00.
• On Friday, November 6th, Orbimed Advisors Llc bought 49,416 shares of Electra Therapeutics stock. The shares were acquired at an average price of $7.85 per share, for a total transaction of $387,915.60.
• On Thursday, November 5th, Orbimed Advisors Llc purchased 156,091 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.31 per share, with a total value of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc purchased 71,367 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.53 per share, with a total value of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc purchased 245,113 shares of Electra Therapeutics stock. The stock was bought at an average price of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc purchased 1,333,333 shares of Electra Therapeutics stock. The stock was bought at an average price of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Stock Performance

NASDAQ:ETRA opened at $7.99 on Wednesday. Electra Therapeutics, Inc. has a 12 month low of $6.86 and a 12 month high of $15.50.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ETRA. Zacks Research upgraded Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. JPMorgan Chase & Co. started coverage on Electra Therapeutics in a report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 target price on the stock. Wall Street Zen raised Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. TD Cowen began coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating on the stock. Finally, Jefferies Financial Group initiated coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating and a $32.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $33.50.

More Electra Therapeutics News

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, through OrbiMed Advisors, reported purchases totaling 92,116 shares across November 6, 9 and 10, at prices ranging from $7.85 to $8.45 per share. Repeated buying by a director may signal confidence in the company, although it does not guarantee future performance. SEC ownership filing
• Neutral Sentiment: A report said short interest stood at zero shares as of November 10, with zero days to cover. That figure does not indicate meaningful reported short positioning, but it conflicts with the report’s description of a “significant increase,” making the short-interest update difficult to interpret.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRP?, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.